Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO

Inclusion Criteria: General conditions: 1. clinically diagnosed as thyroid disease; 2. able and willing to participate in clinical trials and ensure regular follow-up. Eye condition: 1. patients with monocular disease diagnosed by TAO; 2. EUGOGO/NOSPECS grade was mild and CAS score was less than 3; 3. the course of eye disease was less than 12mo and had not been treated in the past. Exclusion Criteria: General situation: 1. patients with poor blood glucose control in recent 3 months, glycosylation ≥ 10% ; 2. blood pressure still fluctuated \> 180/110mmHg after medication; 3. obvious liver and kidney insufficiency; 4. contraindications for the use of glucocorticoids (peptic ulcer, osteoporosis, severe infection, psychosis, etc.); 5. patients with severe abnormal blood coagulation; 6. patients with other systemic immune diseases; 7. any uncontrollable clinical problems (severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumors); 8. history of chronic infection; 9. pregnant and lactating women. Eye conditions: 1. B-ultrasound or CT, MRI found other diseases causing exophthalmos (intraorbital space occupying lesion, inflammatory pseudotumor, neurofibroma, etc.); 2. moderate to severe TAO, in either eye requiring local or systemic treatment; 3. periorbital infectious diseases, hemorrhagic diseases; 4. uveitis, glaucoma, high myopia, diabetic retinopathy and other eye diseases. 5. those who studied the eyes who had a history of arbitrary surgery; 6. those who were considered by the researchers to be excluded.